Results
All twenty stakeholders have reported about recent or future changes in their national reimbursement assessment. In Germany and Austria, new processes have recently been implemented in the law. In the United Kingdom and France new frameworks for the assessment of orphan drugs are developed and Belgium is undergoing ethical debates about reimbursement ( Table 2. ). All stakeholders agreed upon implementation of an European mechanism as future solution for the orphan drug field. Products (ROMP) was passed (1). This regulation was the answer to unfulfilled medical need of patients suffering from rare diseases. Before patients affected by a rare disease were often left without therapeutic options, as investment into research and development of orphan medical products was not profitable for industry (2).
Since the regulation was passed, orphan drug development has immensely increased and health care systems are challenged to find appropriate assessment mechanisms for reimbursement (3) . Public awareness has been raised by changing reimbursement assessments and discontinuation of reimbursement of some orphan drugs in Europe.
Objectives
The research has one main objective:
• To recognize an European overview of perspectives from relevant stakeholders from the field of orphan drugs regarding future changes within the national reimbursement assessment and its evidence requirements for orphan drugs. 
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